MALIGNANT PERIPHERAL NERVE SHEATH TUMOR (MPNST)
Clinical trials for MALIGNANT PERIPHERAL NERVE SHEATH TUMOR (MPNST) explained in plain language.
Never miss a new study
Get alerted when new MALIGNANT PERIPHERAL NERVE SHEATH TUMOR (MPNST) trials appear
Sign up with your email to follow new studies for MALIGNANT PERIPHERAL NERVE SHEATH TUMOR (MPNST), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Personalized cell therapy takes on childhood cancers
Disease control Recruiting nowThis study tests a new treatment called afamitresgene autoleucel in children and young adults aged 2 to 21 with advanced cancers that have a specific marker (MAGE-A4). The treatment uses the patient's own immune cells, modified to attack the cancer. The main goals are to check sa…
Matched conditions: MALIGNANT PERIPHERAL NERVE SHEATH TUMOR (MPNST)
Phase: PHASE1, PHASE2 • Sponsor: USWM CT, LLC • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can a Two-Drug combo stop nerve tumors from turning cancerous?
Disease control Recruiting nowThis trial is testing whether combining two drugs—selumetinib and APG-115—can help people with neurofibromatosis type 1 (NF1) who have nerve sheath tumors that are either pre-cancerous or already cancerous. The study aims to find a safe dose and see if the combination can shrink …
Matched conditions: MALIGNANT PERIPHERAL NERVE SHEATH TUMOR (MPNST)
Phase: PHASE1, PHASE2 • Sponsor: AeRang Kim • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
New hope for sarcoma patients: immunotherapy plus chemo shows promise
Disease control Recruiting nowThis study tests a new combination of drugs (tislelizumab, liposomal doxorubicin, and ifosfamide) as a first treatment for people with advanced soft tissue sarcoma that cannot be removed by surgery or has spread. The goal is to see if this combo shrinks tumors and is safe. About …
Matched conditions: MALIGNANT PERIPHERAL NERVE SHEATH TUMOR (MPNST)
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC